Device type · GGT
Assay, Erythropoietin
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
GGT
Hematology
Device class
Class II
FDA decisions since 2015
2
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Assay, Erythropoietin
- Product code
- GGT
- Device class
- Class II
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7250
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for GGT
Latest FDA decisions
- Access EPO510(k)
K240182 · Decided Apr 22, 2024 · 90 days after receipt
Device type: Assay, Erythropoietin (GGT) · Laboratory Medicine & Pathology
Axis-Shield Diagnostics Limited
K183088 · Decided Aug 2, 2019 · 269 days after receipt
Device type: Assay, Erythropoietin (GGT) · Laboratory Medicine & Pathology
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1249-2025 · Started Feb 3, 2025 · Posted by FDA Feb 28, 2025
Reason given: Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.
Cause as FDA categorized it: Unknown/Undetermined by firm
- Atellica IM Erythropoietin (EPO) Assay (100 Test)Open, Classified
Siemens Healthcare Diagnostics, Inc.
Z-1280-2024 · Started Jan 24, 2024 · Posted by FDA Mar 11, 2024
Reason given: Siemens Healthcare Diagnostics has confirmed an average negative bias of -35% compared to the 3rd World Health Organization (WHO) International Standard (NIBSC code: 11/170) that is proportional across the assay measuring interval. The reference interval as claimed in the Instructions for Use (IFU) is not achieved...
Cause as FDA categorized it: Under Investigation by firm
- ADVIA Centaur Erythropoietin (EPO) Assay (100 Test)Open, Classified
Siemens Healthcare Diagnostics, Inc.
Z-1281-2024 · Started Jan 24, 2024 · Posted by FDA Mar 11, 2024
Reason given: Siemens Healthcare Diagnostics has confirmed an average negative bias of -35% compared to the 3rd World Health Organization (WHO) International Standard (NIBSC code: 11/170) that is proportional across the assay measuring interval. The reference interval as claimed in the Instructions for Use (IFU) is not achieved...
Cause as FDA categorized it: Under Investigation by firm
2 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.